Zobrazeno 1 - 10
of 158
pro vyhledávání: '"P. S. Helliwell"'
Autor:
Iris Verbinnen, Emilio Monte-Boquet, Detlev Parow, Fabienne Lacombe, Andrew Pothecary, Arno W. R. van Kuijk, Laura Harrington, Edita Müllerová, Andreas Pinter, Ulrike Erstling, Andrea Tomasini, Philip S. Helliwell
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 3, Pp 795-815 (2024)
Abstract Introduction Psoriatic arthritis (PsA) is a complex, progressive, and often debilitating disease. Despite recent advances in treatment, numerous unmet needs in patient care persist. Rheumacensus is a multistakeholder, pan-European initiative
Externí odkaz:
https://doaj.org/article/177ca0c0dd2a494c9e8e59080661e07b
Autor:
Philip J. Mease, Ana-Maria Orbai, Oliver FitzGerald, Mohamed Bedaiwi, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young, Philip S. Helliwell
Publikováno v:
Arthritis Research & Therapy, Vol 25, Iss 1, Pp 1-13 (2023)
Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post hoc analysis assessed tofacitinib efficacy on enthesitis by baseline location and severity, and impact on disease activity and
Externí odkaz:
https://doaj.org/article/f0a17b04c72145eab9ba293da31833b6
Autor:
Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff
Publikováno v:
RMD Open, Vol 10, Iss 1 (2024)
Objective Evaluate long-term guselkumab effectiveness across Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)-recognised domains/related conditions of psoriatic arthritis (PsA).Methods Post hoc analyses used data from D
Externí odkaz:
https://doaj.org/article/01b673a8b5db409dbf5ca6cc6e25b045
Autor:
Christopher T. Ritchlin, Atul Deodhar, Wolf‐Henning Boehncke, Enrique R. Soriano, Alexa P. Kollmeier, Xie L. Xu, Federico Zazzetti, May Shawi, Yusang Jiang, Shihong Sheng, Philip S. Helliwell
Publikováno v:
ACR Open Rheumatology, Vol 5, Iss 3, Pp 149-164 (2023)
Objective To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). Methods The phase 3, randomiz
Externí odkaz:
https://doaj.org/article/e4930dc2832540c9ac8cbcbd84cd1cd7
Autor:
Dafna D. Gladman, Philip J. Mease, Paul Bird, Enrique R. Soriano, Soumya D. Chakravarty, May Shawi, Stephen Xu, Sean T. Quinn, Cinty Gong, Evan Leibowitz, Denis Poddubnyy, Lai-Shan Tam, Philip S. Helliwell, Arthur Kavanaugh, Atul Deodhar, Mikkel Østergaard, Xenofon Baraliakos
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Axial involvement constitutes a specific domain of psoriatic arthritis (PsA). Interleukin (IL)-23 inhibitors have demonstrated improvement in axial PsA (axPsA) symptoms, but have not shown efficacy in treating ankylosing spondylit
Externí odkaz:
https://doaj.org/article/29c38a70b6d44575928210e60788a3e0
Autor:
Ana-Maria Orbai, Philip J. Mease, Philip S. Helliwell, Oliver FitzGerald, Dona L. Fleishaker, Rajiv Mundayat, Pamela Young
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-12 (2022)
Abstract Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with tofacitinib assessed dactylitis by location, and the i
Externí odkaz:
https://doaj.org/article/fd02bbe68645406c8131109f93801616
Autor:
Dafna D. Gladman, Laura C. Coates, Joseph Wu, Lara Fallon, Elizabeth D. Bacci, Joseph C. Cappelleri, Andrew G. Bushmakin, Philip S. Helliwell
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-12 (2022)
Abstract Background This study examined the time to clinically meaningful response in patients with active psoriatic arthritis treated with tofacitinib, adalimumab, or placebo switching to tofacitinib. Methods Data were from two phase 3 studies, OPAL
Externí odkaz:
https://doaj.org/article/c9bfa5f71ac240f1b10032db6b72a818
Autor:
Josef S Smolen, Laura C Coates, Eric Lespessailles, Mitsumasa Kishimoto, Rebecca Bolce, Andrew J Bradley, M. Elaine Husni, Joseph F. Merola, Lisa Macpherson, Philip S. Helliwell
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Background/objective The aim of this study was to evaluate relative performance of composite measures in psoriatic arthritis and assess the impact of structural damage and functional disability on outcomes during ixekizumab treatment.Methods Data fro
Externí odkaz:
https://doaj.org/article/ab67bb3c86cd46e68575eba69f2c8c49
Autor:
Proton Rahman, Philip J. Mease, Philip S. Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P. Kollmeier, Elizabeth C. Hsia, Bei Zhou, Xiwu Lin, May Shawi, Chetan S. Karyekar, Chenglong Han
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-12 (2021)
Abstract Background The interleukin-23p19-subunit inhibitor guselkumab effectively treats signs and symptoms of psoriatic arthritis (PsA). We evaluated the effect of guselkumab on fatigue. Methods Across two phase 3 trials of guselkumab (DISCOVER-1,
Externí odkaz:
https://doaj.org/article/f2f76733abb34796af8da2a53d489603
Autor:
Atul Deodhar, Arthur Kavanaugh, Dafna D Gladman, Laura C Coates, Vibeke Strand, Philip S Helliwell, Alexis Ogdie, Lyrica X H Liu, Gregory Kricorian, David Collier, Phillip J Mease
Publikováno v:
RMD Open, Vol 8, Iss 2 (2022)
Objective We used the Study of Etanercept And Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) data set to examine the impact of presence of enthesitis, dactylitis, nail disease and/or psoriasis on treatme
Externí odkaz:
https://doaj.org/article/d27b191a16d84799a9c5014934b2f0a7